Chemed Corp reports strong Q2 2026 earnings, VITAS revenue up 12%

Chemed Corporation announced its second‑quarter 2026 financial results, showing consolidated revenue of $673.3 million, an 8.8% increase year over year. Adjusted diluted earnings per share rose 41.9% to $6.06, and operating cash flow exceeded $173 million, supporting future acquisitions and potential share repurchases.

VITAS Healthcare, the company’s hospice subsidiary, posted net revenue of $443.3 million, up 11.9%, driven by a 6.1% rise in days of care and a 2.4% increase in Medicare reimbursement rates. Average daily census reached 23,687 patients and admissions grew 9% to 19,125. Medicare Cap billing limitation fell sharply to $500,000 from $16.4 million the prior year. Roto‑Rooter, Chemed’s plumbing and drain‑cleaning segment, recorded revenue of $229.9 million, a modest 3.3% increase, with flat earnings.